Holmes Biopharma, Inc.
PINK SHEETS : HLMB

Holmes Biopharma, Inc.

July 19, 2007 09:01 ET

Holmes Biopharma is Selected as a Preferred Service Provider by a Major Pharmaceutical Company

SCOTTSDALE, ARIZONA--(Marketwire - July 19, 2007) - Holmes Biopharma, Inc. (PINK SHEETS:HLMB) is pleased to announce, a major pharmaceutical company known for "continuous outsourcing of Phase I clinical studies valued at $26 million annually", has selected Qualia Clinical Services as one of four preferred service providers.

"This is a momentous accomplishment for Qualia, as this recommendation could potentially translate into over $5 million of additional annual revenue from one sponsor company for Qualia," stated Dr. Sohail Khattak, President and CEO of Qualia Clinical Service.

NOTE: Due to confidentiality requirements, the name of the company cannot be published at this time.

About Holmes:

Holmes Biopharma, Inc. and its wholly owned subsidiary, Qualia Clinical Service, Inc., is a contract research organization focused on providing integrated and cost effective clinical development services that help the pharmaceutical industry introduce new drug products rapidly from laboratory to the market. Holmes is also actively involved in developing new drugs and drug delivery systems. Currently, clinics operate in Omaha, Nebraska and Toronto, Canada. For more information about the company, please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information